Search results for abx831019

Natalizumab, Abbexa, abx831019

Natalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ITGA4/CD49d, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.